Synthetic datasets, which replicate the statistical patterns of real patient populations but carry no risk of privacy disclosures, are becoming part of the vernacular of the pharmaceutical development and real-world evidence landscape.
While the concept is not new, the breadth and seriousness of the COVID-19 pandemic has accelerated interest, with researchers, industry and regulators all looking for evidence that helps inform a...
Talk to experts in synthetic data and they will point to the value of this privacy-sparing approach in enabling access to data, “freeing” and “democratizing” this information for use by...